These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 7520856)

  • 1. Depot antipsychotic drugs. Place in therapy.
    Davis JM; Matalon L; Watanabe MD; Blake L; Metalon L [corrected to Matalon L]
    Drugs; 1994 May; 47(5):741-73. PubMed ID: 7520856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of long-acting antipsychotic medications.
    Spanarello S; La Ferla T
    Curr Clin Pharmacol; 2014; 9(3):310-7. PubMed ID: 23343447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes of psychiatrists toward antipsychotic depot medication.
    Heres S; Hamann J; Kissling W; Leucht S
    J Clin Psychiatry; 2006 Dec; 67(12):1948-53. PubMed ID: 17194274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence.
    Knapp M; Ilson S; David A
    Int Clin Psychopharmacol; 2002 May; 17(3):135-40. PubMed ID: 11981355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
    Masand PS; Gupta S
    Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.
    Kane JM; Aguglia E; Altamura AC; Ayuso Gutierrez JL; Brunello N; Fleischhacker WW; Gaebel W; Gerlach J; Guelfi JD; Kissling W; Lapierre YD; Lindström E; Mendlewicz J; Racagni G; Carulla LS; Schooler NR
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):55-66. PubMed ID: 9452941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The significance of depot medication in the long-term-treatment of schizophrenia].
    Kühn KU; Wiedemann K; Hellweg R; Möller HJ
    Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].
    Breit S; Hasler G
    Nervenarzt; 2016 Jul; 87(7):719-23. PubMed ID: 26597275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes.
    Muirhead D; Harvey C; Ingram G
    Aust N Z J Psychiatry; 2006; 40(6-7):596-605. PubMed ID: 16756586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting depot antipsychotic drugs.
    Pandarakalam JP
    Hosp Med; 2003 Oct; 64(10):603-8. PubMed ID: 14584241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.
    van der Lee APM; Önsesveren I; Wierdsma AI; van Westrhenen R; Beekman ATF; de Haan L; Mulder NCL
    CNS Drugs; 2021 Apr; 35(4):451-460. PubMed ID: 33837915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.